KIR2DS2+ NK cells in cancer patients demonstrate high activation in response to tumour-targeting antibodies.

In the presence of obinutuzumab, KIR2DS2 high NK cells showed enhanced activation compared to KIR2DL3/L2/S2- cells (p<0.05 for 0.01 μg/mL, p<0.01 for 0.1 ug/mL), but did not reach statistical significance compared to KIR2DL3/L2 high NK cells ( Figure 2G ).

also in 111,027 other papers

In this setting, KIR2DL3/L2 high NK cells showed a trend for higher activation compared to KIR2DS2 high NK cells and KIR2DL3/L2/S2- NK cells at both a 10:1 and 20:1 E:T ratio ( Figures 3J-L ).

also in 53,322 other papers